BE536902A - - Google Patents
Info
- Publication number
- BE536902A BE536902A BE536902DA BE536902A BE 536902 A BE536902 A BE 536902A BE 536902D A BE536902D A BE 536902DA BE 536902 A BE536902 A BE 536902A
- Authority
- BE
- Belgium
- Prior art keywords
- neomycin
- sep
- oxytetracycline
- antibiotics
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 32
- 229930193140 Neomycin Natural products 0.000 claims description 23
- 229960004927 neomycin Drugs 0.000 claims description 23
- 239000004100 Oxytetracycline Substances 0.000 claims description 21
- 229960000625 oxytetracycline Drugs 0.000 claims description 21
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 21
- 235000019366 oxytetracycline Nutrition 0.000 claims description 21
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 5
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 2
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 claims description 2
- 239000011149 active material Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 description 16
- 239000003242 anti bacterial agent Substances 0.000 description 13
- 229940088710 antibiotic agent Drugs 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE536902A true BE536902A (cs) |
Family
ID=167429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE536902D BE536902A (cs) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE536902A (cs) |
-
0
- BE BE536902D patent/BE536902A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH667775A5 (fr) | Melange antibacterien, composition alimentaire ou pharmaceutique et procede de preparation de compositions alimentaires. | |
| FR2472388A1 (fr) | Compositions pharmaceutiques contenant un produit corticosteroide | |
| LU87488A1 (fr) | Compositions pharmaceutiques agissant en particulier sur le systeme cardiaque et cardiovasculaire et procede pour les preparer | |
| US4053593A (en) | Medical product combining antimicrobial, antiporasitic and vitamin complex | |
| US5618847A (en) | Medicinal feed for the systemic treatment of ectoparasitic and ectobacterial diseases of fish | |
| CA1103154A (fr) | Compositions pharmaceutiques renfermant des derives organiques de la montmorillonite | |
| FR2480603A1 (fr) | Composition pharmaceutique pour administration par voie orale contenant de la cytidine-diphosphocholine | |
| BE536902A (cs) | ||
| BE507692A (fr) | Perfectionnements apportés aux procedés de préparation de produits thérapeutiques | |
| FR2629346A1 (fr) | Compositions veterinaires synergiquement actives et leur procede de fabrication | |
| EP0959892B1 (fr) | Utilisation de pvp ou povidone pour diminuer le gonflement intestinal | |
| FR2472389A1 (fr) | Compositions antibiotiques contenant un macrolide et un aminoheteroside | |
| BE542038A (cs) | ||
| BE505709A (cs) | ||
| CA1221635A (fr) | Composition a activite pharmaceutique amelioree et utilisation de celle-ci pour des usages veterinaires | |
| BE818335R (fr) | Composition antibacterienne et procede | |
| BE825937A (fr) | Compositions antibacteriennes comprenant un compose de cephalosporine et un compose de penicilline | |
| BE628615A (cs) | ||
| EP0955051A1 (fr) | Composition renfermant des oligomères procyanidoliques (OPC) et un cation divalent | |
| BE541853A (cs) | ||
| BE571622A (cs) | ||
| BE568046A (cs) | ||
| WO2004014405A1 (fr) | Utilisation d’extraits de ginkgo biloba pour favoriser la masse musculaire au detriment de la masse graisseuse | |
| BE581423A (cs) | ||
| CN109730235A (zh) | 一种用于医用食品的防腐剂 |